These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16311730)

  • 1. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
    Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
    Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
    Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.
    Elkord E; Burt DJ; Drijfhout JW; Hawkins RE; Stern PL
    Cancer Immunol Immunother; 2008 Jun; 57(6):833-47. PubMed ID: 18004564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
    Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
    Castro FV; Al-Muftah M; Mulryan K; Jiang HR; Drijfhout JW; Ali S; Rutkowski AJ; Kalaitsidou M; Gilham DE; Stern PL
    Cancer Immunol Immunother; 2012 Jul; 61(7):1005-18. PubMed ID: 22127365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TroVax in colorectal cancer.
    Rowe J; Cen P
    Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
    Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
    J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.
    Jiang HR; Gilham DE; Mulryan K; Kirillova N; Hawkins RE; Stern PL
    J Immunol; 2006 Oct; 177(7):4288-98. PubMed ID: 16982863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.